Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Clinical trial NCT03990896 · RECRUITING
Trial details
- NCT number
- NCT03990896
- Sponsor
- Massachusetts General Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-18
- Primary completion
- 2027-03-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.